08:00 , Nov 16, 2015 |  BioCentury  |  Regulation

Scaling compassion

Nearly two years after a viral media campaign saved seven-year-old Josh Hardy's life and put demands for access to unapproved medicines on front pages, drug companies, FDA, academic bioethicists, and patient advocates are beginning to...
07:00 , May 25, 2015 |  BC Week In Review  |  Company News

Antisense Therapeutics, Cortendo deal

Antisense granted Cortendo exclusive rights to develop and commercialize ATL1103 for endocrinology indications. Antisense will receive $5 million up front and is eligible for up to $105 million in development and commercialization milestones, plus royalties....
07:00 , Oct 6, 2014 |  BC Week In Review  |  Financial News

Antisense Therapeutics completes private placement

Antisense Therapeutics Ltd. (ASX:ANP), Toorak, Australia   Business: Autoimmune, Endocrine/Metabolic, Cancer   Date completed: 2014-09-25   Type: Private placement   Raised: A$1 million ($872,200)   Shares: 8.7 million   Price: A$0.12   Shares after offering:...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Financial News

Antisense Therapeutics proposes private placement

Antisense Therapeutics Ltd. (ASX:ANP), Toorak, Australia   Business: Autoimmune, Endocrine/Metabolic, Cancer   Date announced: 2014-09-25   Type: Private placement   To be raised: Up to A$1.5 million ($1.3 million)   Shares: 13 million   Price:...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Clinical News

ATL1103: Additional Phase II data

An open-label, European and Australian Phase II trial in 26 acromegalic patients showed that 200 mg ATL1103 given 3 times in week 1 followed by twice-weekly 200 mg ATL1103 for 12 weeks met the primary...
07:00 , Sep 8, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) gained $2.63 (11%) to $26.61 on Tuesday after FDA granted breakthrough therapy designation to Nuplazid pimavanserin to treat Parkinson's disease psychosis. The compound has completed a Phase III trial...
00:49 , Sep 4, 2014 |  BC Extra  |  Clinical News

Antisense reports acromegaly data

Antisense Therapeutics Ltd. (ASX:ANP) said 200 mg of ATL1103 twice-weekly met the primary endpoint in a 26-patient, open-label Phase II trial to treat acromegaly. That dosage reduced serum insulin-like growth factor-1 ( IGF-1 ) levels...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
07:00 , Mar 31, 2014 |  BC Week In Review  |  Clinical News

ATL1103: Completed Phase II enrollment

Antisense completed enrollment of 24 acromegalic patients in an open-label, European and Australian Phase II trial evaluating 3 doses of 200 mg ATL1103 in the first week of treatment, followed by once- or twice-weekly 200...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Clinical News

ATL1102: Phase I started

Antisense began an open-label, Australian Phase I trial to evaluate 400 mg subcutaneous ATL1102 on days 1, 3 and 5 with or without G-CSF for 5 days in 10 healthy volunteers. Antisense has rights to...